Story excerpt provided by Dayton Business Journal.
Written by Tristan Navera.
A startup venture founded by one of the members of the Soin family has filed an application for its first drug with the FDA.
Soin Neuroscience, based in Dayton, filed the Orphan Drug Application with the FDA to treat systematic sclerosis, an autoimmune connective tissue disorder that thickens skin and can damage small arteries. The drug, known now by the name TV1001SR, has shown in the first two phases of study to promote blood flow in damaged tissue, using sodium nitrite as its active ingredient.
Click here to read the complete article.
Originally published June 12, 2017.